Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment

International Journal of STD and AIDS

Volumn 10, Issue 8, 1999, Pages 514-521

  Bratt, Göran ^a   Eriksson, Lars E ^a   Sandström, Eric ^a   Gilljam, Gustav ^b   Hinkula, Jorma ^b   Albert, Jan ^b   Redfield, Robert ^c   Wahren, Britta ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

CD4+ lymphocytes; Cellular immunity; Gp 160; HIV; Immunotherapy; Viral load

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS ACTIVATION; VIRUS LOAD;

EID: 0032784515     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462991914591     Document Type: Article

References (46)

1. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362:359-62
2. Wahren B, Morfeldt-Månsson L, Biberfeld G, et al. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection [letter]. N Engl J Med 1986; 315:393-4
3. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990; 87:6058-62
4. Shearer GM, Clerici M. T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: The role of TH1-TH2 cross-regulation. Chem Immunol 1992; 54:21-43
5. Redfield RR, Birx DL. HIV-specific vaccine therapy: Concepts, status, and future directions. AIDS Res Hum Retroviruses 1992; 8:1051-8
6. Rutherford GW, Lifson AR, Hessol NA, et al. Course of HIV-1 infection in a cohort of homosexual and bisexual men: An 11 year follow up study. BMJ 1990; 301:1183-8
7. Phillips AN, Lee CA, Elford J, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991; 337:389-92
8. Munoz A, Carey V, Saah AJ, et al. Predictors of decline in CD4 lymphocytes in a cohort of homosexual men infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1988; 1:396-404
9. Albert J, Abrahamsson B, Nagy K, et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4:107-12
10. Tyler DS, Stanley SD, Nastala CA, et al. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990; 144:3375-84
11. Cease KB, Margalit H, Cornette JL, et al. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide [published erratum appears in Proc Natl Acad Sci]. Proc Natl Acad Sci USA 1987; 84:4249-53
12. Tindall B, Cooper DA. Primary HIV infection: Host responses and intervention strategies [editorial]. AIDS 1991; 5:1-14
13. Ljunggren K, Böttiger B, Biberfeld G, Karlson A, Fenyö EM, Jondal M. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol 1987; 139:2263-7
14. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-8
15. Javaherian K, Langlois AJ, McDanal C, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989; 86:6768-72
16. Rusche JR, Javaherian K, McDanal C, et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 1988; 85:3198-202
17. Palker TJ, Clark ME, Langlois AJ, et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988; 85:1932-6
18. Åkerblom L, Hinkula J, Broliden PA, et al. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 1990; 4:953-60
19. Dolin R, Graham BS, Greenberg SB, et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med 1991; 114:119-27
20. Tacket CO, Baqar S, Munoz C, Murphy JR. Lympho-proliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160. AIDS Res Hum Retroviruses 1990; 6:535-42
21. Orentas RJ, Hildreth JE, Obah E, et al. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990; 248:1234-7
22. Picard O, Achour A, Bernard J, et al. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: Evidence for persistent cell-mediated immunity. J Acquir Immune Defic Syndr 1992; 5:539-46
23. Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337:567-72
24. Salmon-Ceron D, Excler JL, Sicard D, et al. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 1995; 11:1479-86
25. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med 1991; 324:1677-84
26. Wahren B, Bratt G, Persson C, et al. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994; 7:220-9
27. Moss RB, Ferre F, Trauger R, et al. Inactivated HIV-1 immunogen: Impact on markers of disease progression. J Acquir Immune Defic Syndr 1994; 7(Suppl 1):S21-7
28. Fultz PN, Gluckman JC, Muchmore E, Girard M. Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses 1992; 8:313-17
29. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334:1222-30
30. Glaser JB, Volpe S, Aguirre A, Simpkins H, Schiffman G. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis 1991; 164:761-4
31. Mercure L, Lalonde R, Phaneuf D, Brenner B, Wainberg MA. Inhibitory effect of 3′-azido-3′-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2. Clin Diagn Lab Immunol 1994; 1:482-5
32. Sandström E, Wahren B. A randomized double blind placebo controlled trial of therapeutic immunization with rgp160 in human immunodeficiency virus infection. Lancet 1999; 353:1735-42
33. Leandersson A, Bratt G, Hinkula J, et al. Induction of specific T-cell responses in HIV infection. AIDS 1997; 1:1
34. Broliden K, Hinkula J, Bratt G, et al. Analysis of functional responses in HIV-1-infected individuals after vaccination with rgp160. Clin Diagn Virol 1996; 6:115-26
35. Scarlatti G, Lombardi V, Plebani A, et al. Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. AIDS 1991; 5:1173-8
36. Lundholm P, Wahren M, Sandstrom E, et al. Autoreactivity in HIV-infected individuals does not increase during vaccination with envelope rgp160. Immunol Lett 1994; 41:147-53
37. Bratt G, Sandström E, Albert J, Samson M, Wahren B. The influence of MT-2 tropism on the prognostic implications of the Δ32 deletion in the CCR-5 gene. AIDS 1997; 11:1415-19
38. Ginsburg C, Salmon-Ceron D, Vassilief D, et al. Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment [letter]. AIDS 1997; 11:388-9
39. Loomis LD, Deal CD, Kersey KS, Burke DS, Redfield RR, Birx DL. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:13-26
40. Rosenberg E, Billingsley J, Caliendo A, et al. Vigorous HIV-1 specific CD4+ T-cell responses associated with control of viremia. Science 1997; 278:1447-50
41. Birx DL, Redfield RR. Immunotherapeutic strategies in the treatment of HIV infection and AIDS. Curr Opin Immunol 1993; 5:600-7
42. Birx D, Davis C, Ruiz N, et al. Results of a phase III double-blinded multicenter, placebo controlled HIV therapeutic vaccine trial (Abstract). XIth International Conference on AIDS, Vancouver, 7-12 July, 1996
43. Tsoukas CM, Raboud J, Bernard NF, et al. Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. AIDS Res Hum Retroviruses 1998; 14:483-90
44. McCarthy M. Trial results thwart HIV-vaccine hopes [news]. Lancet 1996; 347:1173
45. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33
46. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy. N Engl J Med 1997; 337:734-9